Neuphoria Therapeutics Inc. Fair Value Adjustment of Warrants
Neuphoria Therapeutics Inc. (NEUP) reported Fair Value Adjustment of Warrants of -$1.73 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-09-18
- Neuphoria Therapeutics Inc. fair value adjustment of warrants for the quarter ending 2026-06-30 was -$486.20K, a 126.80% decline year-over-year.
- Neuphoria Therapeutics Inc. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$255.41K, a 123.71% decline year-over-year.
- Neuphoria Therapeutics Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$5.38M.
- Neuphoria Therapeutics Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was $4.39M.
- Neuphoria Therapeutics Inc. fair value adjustment of warrants for fiscal 2026 was -$1.73M.
- Neuphoria Therapeutics Inc. fair value adjustment of warrants for fiscal 2025 was -$956.34K.
- Neuphoria Therapeutics Inc. fair value adjustment of warrants for fiscal 2024 was -$338.98K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$486.20K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$741.61K derived: sum of 2 quarters · filed 2026-09-18 | -$6.12M derived: sum of 3 quarters · filed 2026-09-18 | -$1.73M 10-K · filed 2026-09-18 |
| 2026-03-31 | -$255.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | -$5.63M derived: sum of 2 quarters · filed 2026-05-15 | -$1.24M 10-Q · filed 2026-05-15 | $569.92K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | -$5.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$988.71K 10-Q · filed 2026-02-17 | $825.33K derived: sum of 3 quarters · filed 2026-09-18 | $1.90M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | $4.39M 10-Q · filed 2025-11-14 | $6.20M derived: sum of 2 quarters · filed 2026-09-18 | $7.28M derived: sum of 3 quarters · filed 2026-09-18 | $6.40M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $2.89M derived: sum of 2 quarters · filed 2026-09-18 | $2.01M derived: sum of 3 quarters · filed 2026-09-18 | -$956.34K 10-K · filed 2026-09-18 |
| 2025-03-31 | $1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $195.87K derived: sum of 2 quarters · filed 2026-05-15 | -$2.77M 10-Q · filed 2026-05-15 | -$3.11M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$881.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$3.85M 10-Q · filed 2026-02-17 | -$4.19M derived: sum of 3 quarters · filed 2026-02-17 | |
| 2024-09-30 | -$2.97M 10-Q · filed 2025-11-14 | -$3.31M derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-06-30 | -$338.98K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | -$338.98K 10-K · filed 2025-09-29 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |